Premier Alternatives

NewLimit

South San Francisco, CA · Founded 2021 · Privately Held (backing)

Developer of precision medicines designed for epigenetic reprogramming to restore youthful function in aging cells. NewLimit is based in South San Francisco, CA and was founded in 2021. It was valued at $1.6 billion at its early-stage round in Oct 2025, the last priced event on record. It has raised $247 million across 2 recorded rounds; the latest was a $130 million later-stage round in May 2025.

PMV mark · valuation
$1.6B
Oct 2026
Priced at
its early-stage round
Oct 2025
Total raised
$247.3M
Last round
Later Stage VC
May 2025

NewLimit key facts

as of Oct 2026
  • Developer of precision medicines designed for epigenetic reprogramming to restore youthful function in aging cells.
  • NewLimit is valued at approximately $1.6B as of Oct 2026, set at its early-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $247.3M across 2 recorded rounds; the latest was Later Stage VC ($129.8M) in May 2025.
  • Notable investors include Khosla Ventures, Founders Fund, Draper Associates, Abstract Ventures, Valor Equity Partners — 24 tracked in total.
  • NewLimit has filed 3 Form Ds with the SEC since 2023, most recently May 2025 ($129.8M sold to 38 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$1.6B

Valued at $1.6B at its early-stage round, Oct 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of NewLimit with a free account
  • ·The complete investor list: 24 names
  • ·Watch NewLimit: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

NewLimit funding rounds

2 rounds
May 2025Later Stage VC$129.8MSEC filing▮
May 2023Later Stage VC$72.2MSEC filing▮
Full funding history →

NewLimit valuation

NewLimit was valued at $1.6 billion at its early-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has NewLimit raised?

NewLimit has raised $247 million across 2 recorded rounds since 2023. The largest was a $72.2 million later-stage round in May 2023; the most recent was a $130 million later-stage round in May 2025.

NewLimit has filed 3 Form Ds with the SEC since 2023, most recently in May 2025 ($130 million sold to 38 investors).

NewLimit investors

24 investors are on record for NewLimit, including Khosla Ventures, Founders Fund, Draper Associates and Abstract Ventures. By type, the record holds 9 venture capital firms, 4 angel investors and 3 private investors. The later-stage round in May 2025 drew 38 investors.

About NewLimit

Developer of precision medicines designed for epigenetic reprogramming to restore youthful function in aging cells. The company applies single-cell genomics, machine learning, and functional assays to study aging, identify epigenetic targets, and develop messenger ribonucleic acid-based therapies that enhance metabolic function in liver cells, enabling researchers and medical professionals to advance treatments for age-related conditions and improve human healthspan.

Sector
Healthcare
HQ
South San Francisco, CA, United States
Founded
2021
Employees
43
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.